KALA BIO Receives Nasdaq Delisting Notice for Failing Minimum Bid Price Requirement
KALA sits 19% above its 52-week low of $0.51 on light trading volume (0.1× avg).
Summary
KALA BIO, Inc. has received a notice from Nasdaq regarding its non-compliance with the minimum $1.00 bid price rule, initiating a 180-day compliance period to avoid delisting.
Key Events · Corporate Governance and Compliance · KALA
-
Nasdaq Minimum Bid Price Deficiency
KALA BIO, Inc. received a notice on January 20, 2026, from Nasdaq indicating non-compliance with the minimum $1.00 bid price rule, based on its closing bid price for the 30 consecutive business days between December 3, 2025, and January 16, 2026.
-
180-Day Compliance Period Initiated
The company has been granted a 180-calendar-day period, until July 20, 2026, to regain compliance. To do so, its common stock must maintain a minimum closing bid price of $1.00 for at least ten consecutive business days.
-
Potential for Reverse Stock Split
If compliance is not met by July 20, 2026, the company may be eligible for an additional 180-day period if it meets other listing standards and provides notice of its intention to cure the deficiency, potentially through a reverse stock split.
-
No Immediate Delisting Impact
The notice has no immediate effect on the listing or trading of KALA BIO's common stock, which will continue on Nasdaq during the compliance period, subject to other listing requirements.
Analysis · KALA · Life Sciences
KALA BIO, Inc. has received a critical notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, a significant event that threatens its continued listing on The Nasdaq Capital Market. This notice follows a period of intense financial activity for the company, including a recent At-The-Market offering and debt restructuring earlier in January. The company now faces a 180-day compliance period to regain the minimum bid price, which will likely require a substantial increase in its stock price or a reverse stock split. Failure to comply could lead to delisting, severely impacting liquidity and investor confidence. This development adds considerable pressure to the company's already challenging financial situation.
At the time of this filing, KALA was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.8M. The 52-week trading range was $0.51 to $20.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.